Charles River Laboratories International (NYSE: CRL) and OncoGenex Pharmaceuticals (NASDAQ:ACHV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Profitability

This table compares Charles River Laboratories International and OncoGenex Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Charles River Laboratories International 10.13% 27.02% 8.84%
OncoGenex Pharmaceuticals N/A -94.42% -71.68%

Institutional and Insider Ownership

95.8% of Charles River Laboratories International shares are held by institutional investors. 2.2% of Charles River Laboratories International shares are held by insiders. Comparatively, 3.3% of OncoGenex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Charles River Laboratories International and OncoGenex Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Charles River Laboratories International $1.81 billion 2.76 $435.89 million $3.81 27.57
OncoGenex Pharmaceuticals N/A N/A N/A ($5.72) -0.47

Charles River Laboratories International has higher revenue and earnings than OncoGenex Pharmaceuticals. OncoGenex Pharmaceuticals is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Charles River Laboratories International has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, OncoGenex Pharmaceuticals has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Charles River Laboratories International and OncoGenex Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Charles River Laboratories International 0 4 3 0 2.43
OncoGenex Pharmaceuticals 0 0 0 0 N/A

Charles River Laboratories International presently has a consensus target price of $96.93, suggesting a potential downside of 7.71%. Given Charles River Laboratories International’s higher probable upside, equities analysts plainly believe Charles River Laboratories International is more favorable than OncoGenex Pharmaceuticals.

Summary

Charles River Laboratories International beats OncoGenex Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

About Charles River Laboratories International

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company’s clients’ manufacturing activities.

About OncoGenex Pharmaceuticals

Achieve Life Sciences, Inc., formerly OncoGenex Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company’s product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell’s adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27).

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.